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Available online 01 March 2017Mother-infant contact has a critical role on brain development and behavior. Experiencing early-life adversities
(such as maternal separation stress or MS in rodents) results in adaptations of neurotransmission systems,
which may subsequently increase the risk of depression symptoms later in life. In this study, we show that Oxy-
tocin (OT) exerted antioxidant and anti-inﬂammatory properties. Previous studies indicate that neuroinﬂamma-
tion and mitochondrial dysfunction are associated with the pathophysiology of depression. To investigate the
antidepressant-like effects of OT, we applied MS paradigm (as a valid animal model of depression) to male
mice at postnatal day (PND) 2 to PND 14 (3 h daily, 9 AM to 12 AM) and investigated the depressive-like behav-
iors of these animals at PND 60 in different groups. Animals in this work were divided into 4 experimental
groups: 1) saline-treated, 2) OT-treated, 3) atosiban (OT antagonist)-treated and, 4) OT+ atosiban-treated
mice. We used forced swimming test (FST), splash test, sucrose preference test (SPT) and open ﬁeld test (OFT)
for behavioral assessment. Additionally, we used another set of animals to investigate the effects of MS and dif-
ferent treatments on mitochondrial function and the expression of the relevant genes for neuroinﬂammation.
Our results showed that MS provoked depressive- like behaviors in the FST, SPT and splash test. In addition,
our molecular ﬁndings revealed that MS is capable of inducing abnormal mitochondrial function and immune-
inﬂammatory response in the hippocampus. Further, we observed that treating stressed animals with OT (intra-
cerebroventricular, i.c.v. injection) attenuated the MS-induced depressive-like behaviors through improving
mitochondrial function and decreasing the hippocampal expression of immune-inﬂammatory genes. In conclu-
sion, we showed that MS-induced depressive-like behaviors in adult male mice are associated with abnormal
mitochondrial function and immune-inﬂammatory responses in the hippocampus, and activation of OTergic
system has protective effects against negative effects of MS on brain and behavior of animals.
© 2017 Elsevier Inc. All rights reserved.Keywords:
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a.tums.ac.ir (A.R. Dehpour).1. Introduction
Mother-infant contact has an important effect on the shaping of
newborns' physiological system along with the development/matura-
tion of the brain and behavior. In this regard, it has been shown that
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which contributes to the shaping of behavioral and physiological pro-
gressions, and subsequently increasing social adaptation (Feldman
et al., 2010). Research studies indicate that early life exposure to
stressors and traumatic events increase the risk for developing neuro-
psychiatric disorders in later life (Diekstra and Wolters, 1992; Heim
and Nemeroff, 2001; Johnson et al., 2002; Millstein and Holmes, 2007;
Kendler et al., 2010). In rodents, early life maternal separation stress
(as a valid animal model of depression) negatively affects different
brain areas such as amygdala, prefrontal cortex and hippocampus and
alters neurotransmission (Millstein and Holmes, 2007; Amini-Khoei
et al., 2015; Amiri et al., 2016a). These bio-behavioral and neurochemi-
cal alterations are associated with the development of a variety of neu-
ropsychiatric disorders such as depression in both human and animals
in adulthood (Zlotnick et al., 1995; Brodsky et al., 2001; Roy, 2002;
Diehl et al., 2012). Additionally, research evidence has shown that
early life stress is capable of altering normal mitochondrial function in
the brain by affecting the antioxidant system and overproduction of
free radicals, including reactive oxygen species (ROS) (Diehl et al.,
2012; Hendricks et al., 2012). ROS production Oxidative stress is sug-
gested to be produced due to an imbalance between oxidative and anti-
oxidative system, and plays an important role in the pathogenesis of a
wide range of neuropsychiatric diseases such as depression (Sarandol
et al., 2007; Pandya et al., 2013; Zhang and Yao, 2013). Depression is
considered as a mental disorder which is accompanied by oxidative
damage and a signiﬁcant impairment in antioxidant system (Maurya
et al., 2016). Ample evidence suggests that mitochondria are among
the main targets of stress, and abnormal mitochondrial activity is asso-ciated with the initiation of immune-inﬂammatory responses in the
brain (Hagberg et al., 2014; Picard et al., 2014).
On the other hand, neuroinﬂammation is amajor contributing factor
in the pathophysiology of psychiatric disorders such as depression
(Hurley and Tizabi, 2013). It has been shown that chronic exposure to
stress triggers the immune-inﬂammatory responses in thebrain, and in-
duces depressive-like behaviors in animals (Frank et al., 2013).
Oxytocin, a nonapeptide neuromodulator, plays a crucial role in the
regulation of mammalian social behaviors, stress responses, emotions
and reproductive behaviors (Higuchi, 1995; Boccia et al., 2013; Love,
2014; Shamay-Tsoory and Young, 2016). Recent investigations on the
OTergic system have been shown that this system could be considered
as a potential pharmacologic target in psychiatric disorders that can
improve some symptoms of social dysfunctions in autism, schizophre-
nia, social anxiety and borderline personality disorder (Shamay-
Tsoory and Abu-Akel, 2016). Recently, OTergic system has gained the
attention of researchers for its antidepressant properties (McQuaid
et al., 2014).
Although there is evidence indicating the association betweenmito-
chondrial dysfunction and neuroinﬂammation (Hagberg et al., 2014;
Picard et al., 2014; Möller et al., 2015), but few studies have focused to
investigate whether MS stress is accompanied by immune-
inﬂammatory responses. Further, considering the beneﬁcial effects of
OT as an pharmacological agent with anti-inﬂammatory and antioxi-
dant properties (Karelina et al., 2011), we aimed to investigate the ef-
fects of exogenous OT on the depressive-like behaviors in an animal
model of early life stress considering the role of immune-
inﬂammatory responses and mitochondrial function.2. Materials and methods
2.1. Animals and housing conditions
Pregnant NMRI mice (gestation day 1) were purchased from Pasteur Institute of Iran, and used in current study. Animals were maintained under
standard laboratory conditions as 12-h light/dark cycle, temperature 22± 1 °C and free access to food and water ad libitum. The birth date was con-
sidered as postnatal day 0 (PND 0). After birth, at PND 2 the offsprings were subjected to MS paradigm. For this purpose, pups were separated from
their mothers for 3 h daily during PND 2-14, beginning at 09:00 a.m., andwere returned to their mothers after the 3 h separation period (Desbonnet
et al., 2010; Amini-Khoei et al., 2015; Amiri et al., 2016a). At the end of PND 14, pupswere returned to theirmothers cages and remained undisturbed
till PND 21. On PND 21, male mice were weaned and kept in groups (4 mice per cage) until experiment day PND 60. We did not touch the control
animals and they left undisturbed and were weaned on PND 21 and grouped in cages (n = 4) till PND 60 for experiments.
All procedures in this study were done in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory An-
imals (NIH publication # 80-23) and institutional guidelines for animal care and use (Department of Pharmacology, Faculty of Medicine, TehranUni-
versity of Medical Sciences). All tests were performed between 10:00 a.m. to 02:00 p.m. All experimental groups involved 3–8 mice and we tried to
minimize the use of animals and to improve their well-being.
2.2. Study design
This research studywas carried out in two different parts. For the ﬁrst part, we applied OT at different doses (0.5, 0.75, 1 and 1.25 μg/mouse in 1 μl)
to treat both control and MS mice in order to ﬁnd the effective and sub-threshold doses of OT. On the second part, both MS and control mice were
subjected to behavioral tests including forced swimming test (FST), open-ﬁeld test (OFT), splash test and sucrose preference test (SPT). The treatment
as primary factorwas assigned randomly to both control andMSmice as follows 1) saline, 2) OT (1 μg/mouse in 1 μl, 30min before test), 3) atosiban, a
speciﬁc antagonist of OT receptor, (10 μg/mouse in 1 μl, 15 min before test), and 4) atosiban + OT (atosiban 15 min prior to OT injection).
All behavioral experimentswere performed in adult mice (PND60-62). At the end of our study, the animals were sacriﬁced (decapitated) and the
murine hippocampi were separated on ice-cold surface and directly snapped freeze in liquid nitrogen and kept in freezer−80 °C until the start of
molecular assays. Above-mentioned drugs were injected intracerebroventricularly (i.c.v.) according to the method described by Haley and McCor-
mick (Haley and McCormick, 1957). The doses and time of drug administrations were selected according to the previous studies (Qi et al., 2012;
Han et al., 2014; Amini-Khoei et al., 2016) and our pilot studies.
2.3. Behavioral experiments
2.3.1. Forced swimming test (FST)
In the FST, the increased immobility time is associated with despair behavior reﬂecting the depressive-like behavior in rodents (Porsolt et al.,
1977; Haj-Mirzaian et al., 2016a). Mice were separately placed in an open glass cylinder (diameter: 10 cm, height: 25 cm) ﬁlled with 19 cm water
(23±1 °C).Micewere allowed to swim for a 6min period and the immobility timewas recorded during the last 4min of the test by an experimenter
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only those essential movements to maintain its head above the water.
2.3.2. Open-ﬁeld test (OFT)
WeusedOFT to investigate the effects of housing condition and treatments onmotor function (Kulesskaya and Voikar, 2014). TheOFT devicewas
made of white opaque Plexiglas (50 cm × 50 cm × 30 cm) which was dimly illuminated. Each animal was gently placed on the central zone of the
apparatus (30 cm × 30 cm) and its behavior was recorded using a camera for 5 min and evaluated by Ethovision software version 8 (Noldus,
Netherlands). The distance moved (horizontal activity) and the number of rearings (vertical activity) was measured in OFT. Ethanol 70% was used
to clean the apparatus after testing of each mouse.
2.3.3. Splash test
Self-care andmotivational difﬁculties are investigated in rodents byusing splash test. In this test, grooming activity in response to a sweet solution
is considered as an indirect measure of palatable solution intake. A 10% sucrose solution was spurted on the dorsal coat of mice while they were in
their home cages andmicewere videotaped for 5 min. In this test, grooming activity behaviors include nose/face grooming, head washing, and body
grooming (Ducottet et al., 2003; Marrocco et al., 2014; Haj-Mirzaian et al., 2016a).
2.3.4. Sucrose preference test (SPT)
The SPT was done to investigate the hedonic state in animals (Wallace et al., 2009; Amini-Khoei et al., 2015; Amiri et al., 2016a). In this test, two
bottles of tap water were introduced to each mouse for the ﬁrst two days. Then, for the second two days, a bottle containing 1% sucrose solution
substituted one of the bottles. For sucrose preference test, animals were deprived of food and water for 5 h, and then SPT was carried out during
1 h using two bottles in each cage, one contained 1% sucrose solution and the other one was ﬁlled with tap water. SPT was measured using the fol-
lowing equation: sucrose preference = sucrose consumed/(sucrose consumed + tap water consumed).
2.4. Mitochondrial factors
Animals were sacriﬁced and hippocampiwere separated on ice-cold surface and immediately snapped freeze in liquid nitrogen. Homogenization
was done at 4 °C using cold mannitol solution containing 0.225M D-mannitol, 75 mM sucrose, and 0.2 mM EDTA based on our previous studies and
other documents (Lores-Arnaiz et al., 2010; Amiri et al., 2017). The homogenization was done in a glass homogenizer with a Teﬂon pestle and cen-
trifuged at 1000 ×g for 10 min at 4 °C to remove the nuclei, unbroken cells, and other non-subcellular debris.
The supernatantwas centrifuged at 10,000 ×g for 10min as a source of hippocampalmitochondria. The heavymitochondrial fractionwas collect-
ed and re-suspended in the mannitol solution and, re-centrifuged twice at 10,000 ×g for 10 min. The resulting pellet (P2 fraction), including both
synaptic and non-synaptic mitochondria was re-suspended in desired buffer based on oxidative stress markers including ROS production, ATP,
and glutathione (GSH) (Ahadpour et al., 2016). To keep the uniformity of experimental condition, the mitochondrial samples (100 μg protein/ml)
were selected in all oxidative stress experiments.Mitochondrial protein concentrationwas determined by the Coomassie blue protein-bindingmeth-
od using BSA as the standard (Bradford, 1976).
2.4.1. Measurement of ROS formation
Mitochondrial ROS formation was measured using DCFH-DA reagent using HITACHI ﬂuorescence spectrophotometer at excitation and emission
wavelengths of 495 and 520 nm, respectively (Jafarian et al., 2013). Brieﬂy, mitochondria (normalized to 100 μg of mitochondrial protein) were in-
cubated in respiratory buffer containing 0.32 mM sucrose, 10 mM Tris, 20 mMMOPS, 0.05 mM EGTA, 0.5 mMMgCl2, 0.1 mM KH2PO4, and 5 mM
sodium succinate and 2′, 7′-dichloroﬂuorescein diacetate (DCFH-DA) (ﬁnal quantity of 10 μM). The ﬂuorescence intensity was recorded in 5, 30
and 60 min intervals for 1 h and reported as a percent value based on the formula × 100:
Fluorescence intensity in treated groups−Fluorescence intensity in saline group mitochondriað Þ
Fluorescence intensity in saline group−Fluorescence intensity of DCF in media without mitochondriað Þ
2.4.2. ATP assay
For ATP assay, 0.5 ml of mitochondrial homogenate in TCA (6%) was pooled with 0.5 ml of KOH 0.05 M (on ice), then, supplemented with 1 ml
deionized water; after 2 min, 650 μl of KH2PO4 (0.05 M) was added, and vortexed. After ﬁltering, ATP level in each sample was determined using
luciferase enzyme based on criteria described previously (Eskandari et al., 2012; Haj-Mirzaian et al., 2016a). Bioluminescence intensity was mea-
sured using Sirius tube luminometer (Berthold Detection System, Germany).
2.4.3. Glutathione (GSH) assay
Glutathione levels were measured according to the method described by Jayakumar et al. (Jayakumar et al., 2014), using 5, 5′-dithiobis- (2-
nitrobenzoic acid) as an indicator. For this purpose, 0.1 ml of supernatant was added into 0.1 mol·L−1 of phosphate buffer and 0.04% DTNB in a
total volume of 3.0 ml (pH 7.4). The generated color wasmeasured at 412 nm using a spectrophotometer (UV-1601 PC, Shimadzu, Japan). GSH con-
tent was considered as μg/mg protein.
2.5. Nitrite assay
Nitrite, as the nitric oxide (NO) end-product, was measured in our samples according to our previous studies (Amiri et al., 2015a, 2016b). Color-
imetric assay based on the Griess reaction was used to assess the nitrite concentration. In brief, 100 μl of samples were mixed with 100 μl Griess re-
agent. Following 10min incubation at room temperature, absorbancewasmeasured at 540 nm in an automated plate reader. Concentration of nitrite
was calculated by reference to a standard curve of sodium nitrite (Sigma, USA) and normalized to the mg protein of each sample.
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At ﬁrst total RNA using TRIzol reagent (Invitrogen) was extracted from hippocampi. Alterations in the mRNA levels of genes were determined
using qRT-PCR after the reverse transcription of 1 μg of RNA from each sample using PrimeScript RT reagent kit (Takara Bio, Inc., Otsu, Japan).
qRT-PCR was done on a light cycler device (Roche Diagnostics, Mannheim, Germany) using SYBR Premix Ex Taq technology (Takara Bio). Thermal
cycling conditions were including an initial activation step for 30 s at 95 °C afterwards 45 cycles as well as a denaturation step for 5 s at 95 °C and
a combined annealing/extension step for 20 s at 60 °C.Melting curve analysis was performed to certifywhether all primers yielded a single PCR prod-
uct. The genes and their primers are listed in Table 1. Histone H2A variant, H2afz, was used as a house-keeping gene (normalizer) and alterations in
expression of each target mRNA in comparison with H2afzwasmeasured based on 2−ΔΔCt relative expression formula, as described in our previous
publications (Amini-Khoei et al., 2016; Haj-Mirzaian et al., 2016b).
2.7. Statistics
The sample size was calculated by G power software (ver.3.1.7, Franz Faul, Universitat Kiel, Germany). We set α error at 0.05 and power (1-β) at
0.8 and the essential total sample size for each groupwas calculated as 6–8 in behavioral assessments and 3–6 inmolecular experiments. In addition,
we calculated the power value in each investigational group and have founded that the power values were N0.8 in all ANOVA analyses. Comparison
between the groups was analyzed using t-test and one-way analysis of variance (ANOVA) followed by tukey's post hoc tests using the Graph-pad
prism software (version 6). P b 0.05 was considered statistically signiﬁcant.3. Results
3.1. MS paradigm provoked depressive-like behaviors in adult male mice
Our results indicated that MS provoked depressive-like behaviors in
adult malemice. t-test analysis revealed that the duration of immobility
time in the FST was signiﬁcantly increased in MS mice in comparison
with control counterparts (t = 6.576, df = 10, P b 0.001, Fig. 1A). Fur-
ther, in comparison with control mice, we showed that MS induced a
signiﬁcant reduction in grooming activity time in the splash test (t =
9.703, df= 10, P b 0.001, Fig. 1B). Moreover, in the SPT,MS signiﬁcantly
reduced the consumption of sucrose solution in MS mice when com-
pared to controls (t = 5.334, df = 10, P b 0.001, Fig. 1C). In the OFT, t-
test analysis showed that the total distance moved (horizontal activity)
(t = 9.488, df = 10, P b 0.001, Fig.1D), and also the number of rearings
(vertical activity) t = 3.496, df = 12, P b 0.01, Fig.1E) signiﬁcantly in-
creased in MS group in comparison to control group.3.2. Oxytocin attenuated the depressive-like behaviors-induced by MS
Different doses of OT (0.5, 0.75, 1 and 1.25 μg/mouse in 1 μl, i.c.v.)
were used to determine the effective dose of OT on depressive-like be-
haviors in both MS and control animals. One-way ANOVA analysis re-
vealed that there are signiﬁcant differences between different groups
in the FST (F (9, 51) = 27.40, P b 0.001, Fig. 2A), splash test (F (9,
57) = 95.63, P b 0.001, Fig. 2B), SPT (F (9, 51) = 35.63, P b 0.001,
Fig. 2C), horizontal activity of the OFT (F (9, 61) = 48.59, P b 0.001,
Fig. 2D) and vertical activty of the OFT (F (9, 61) = 19.59, P b 0.001,
Fig. 2E).
Results of post-test analysis showed that treatment with OT
(1.25 μg/mouse in 1 μl) produced signiﬁcant changes in depressive-
like behaviors in control mice when compared to saline-treated control
mice in the FST (P b 0.001), splash test (P b 0.001), and SPT (P b 0.05).
However, other doses of OT had no signiﬁcant effect on above-Table 1
Primer sequences.
Primer name Forward sequence Reverse sequence
H2afz TCATCGACACCTGAAATCTAGGA AGGGGTGATACGCTTTACCTTTA
Tnf-α CTGAACTTCGGGGTGATCGG GGCTTGTCACTCGAATTTTGAGA
Il-1β GAAATGCCACCTTTTGACAGTG TGGATGCTCTCATCAGGACAG
Tlr4 ATGGCATGGCTTACACCACC GAGGCCAATTTTGTCTCCACA
Myd88 ATCGCTGTTCTTGAACCCTCG CTCACGGTCTAACAAGGCCAG
Nlrp3 ATCAACAGGCGAGACCTCTG GTCCTCCTGGCATACCATAGAmentioned behavioral tests in control animals. In addition, OT (0.5,
0.75, 1 and 1.25 μg/mouse in 1 μl) made no signiﬁcant changes in hori-
zontal and vertical activities in the OFT in control mice (P N 0.05, Fig. 2D
and E, respectively). Post-test analysis demonestrated that unlike doses
of 0.5 and 0.75 μg/mouse in 1 μl, OT in doses of 1 and 1.25 μg/mouse in
1 μl signiﬁcantly attenuated the depressive-like behaviors of MSmice in
the FST (P b 0.01 and P b 0.001), splash test (P b 0.05 and P b 0.01), and
SPT (P b 0.05 and P b 0.01). In the OFT, tukey's post-hoc analysis re-
vealed that administration of OT (1.25 μg/mouse in 1 μl) toMSmice sig-
niﬁcantly reduced horizontal activity when compared to saline-treated
MS mice (P b 0.05). However, MS mice showed no response to the OT
effects in vertical activity in OFT (P N 0.05). Our results showed that un-
like control mice, dose 1 μg/mouse in 1 μl in MS mice made signiﬁcant
changes in behavioral tests relevant to depression. Since dose 1.25 μg/
mouse in 1 μl produced signiﬁcant alterations in the behavior of both
control andMSmice, we selected dose 1 μg/mouse in 1 μl for ourmolec-
ular experiments. In order to conﬁrm the antidepressant-like effect of
OT, we used atosiban (ATO, 10 µg/mouse in 1 µl) alone and or in combi-
nation with OT (1 µg/mouse in 1 µl). One-way ANOVA analysis
revealed that there are signiﬁcant differences between groups in the
FST (F (7, 39) = 39.23, P b 0.001, Fig. 3A), splash test (F (7, 42) =
119.1, P b 0.001, Fig. 3B), SPT (F (7, 39) = 47.93, P b 0.001, Fig. 3C),
horizontal activity of the OFT (F (7, 48) = 42.78, P b 0.001, Fig. 3D)
and vertical activty of the OFT (F (7, 48) = 14.33, P b 0.001, Fig. 3E).
As shown in Fig. 3, administration of atosiban in control mice signiﬁ-
cantly increased the depressive-like behaviors in the FST (P b 0.05),
splash test (P b 0.05) and SPT (P b 0.05). Furthermore, co-treated of
atosibanwith OT in control groups failed to produce signiﬁcant changes
in comparison with saline- treated control mice in the FST, SPT, splash
test and OFT. Treating MS mice with atosiban produced any signiﬁcant
alterations in the aformentioned behavioral tests when compared
to saline-treated MS mice. Tukey’s analysis showed that co-
administration of atosiban plus OT signiﬁcantly increased the
depressive-like behaviors of MS mice in the splash test (P b 0.05), and
SPT (P b 0.05). In the OFT, post-hoc analysis revealed that co-
administration of atosiban with OT to MS mice failed to produce signif-
icant changes in horizontal activity and vertical activitywhen compared
to saline-treated MS mice.3.3. Effects of MS and OT on GSH concentrations in the hippocampus
Tukey's analysis showed that GSH levels in the hippocampus of MS
mice were signiﬁcantly decreased when compared to control animals
(P b 0.01, Table 2). Treating MS mice with OT (1 μg/mouse in 1 μl) sig-
niﬁcantly restored the GSH levels in comparison with saline-treated
Fig. 1. Effects of MS on depressive-like behaviors in male mice: FST (A), splash test (B), SPT (C), OFT (D and E). Values are presented as the mean ± S.E.M from 6 to 8 animals and were
analyzed using t-test. **P b 0.01 and ***P b 0.001 compared with the control mice.
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atosiban + OT signiﬁcantly decreased the levels of GSH in comparison
with saline-treated controls (P b 0.01). Atosiban alone or as co-
administrated with OT failed to reverse the beneﬁcial effects of OT on
hippocampal GSH levels inMSmice. This resultmight be due to the dys-
function of OT receptors following MS paradigm. Recently, we have
showed that MS led to dysfunction of OTergic system in the brain
(Amini-Khoei et al., 2016).Fig. 2. Effects of several doses of oxytocin (0.5, 0.75, 1 and 1.25 μg/mouse in 1 μl, i.c.v.) on depress
are showed as themean± S.E.M from 6 to 8 animals andwere analyzed using one-way ANOVA
saline-treated control mice, #P b 0.05, ##P b 0.01 and ###P b 0.001 compared with the saline-tr3.4. Effects of MS and OT on ATP levels in the hippocampus
Our results showed that MS signiﬁcantly reduced ATP levels in the
hippocampus of MS mice in comparison with control mice (P b 0.01,
Table.2). TreatingMSmicewith OT (1 μg/mouse in 1 μl) signiﬁcantly in-
creased ATP levels in the hippocampus of MS mice when compared to
saline-treated MS mice (P b 0.01). Unlike MS group, administration of
atosiban, as well as atosiban + OT in control animals signiﬁcantlyive-like behaviors inmalemice: FST (A), splash test (B), SPT (C), andOFT (D and E). Values
followed by Tukey's post hoc test. *P b 0.05, **P b 0.01 and ***P b 0.001 comparedwith the
eated MS mice. OT: oxytocin.
Fig. 3. Effects of co-administration of oxytocin (1 µg/mouse in 1µl, i.c.v.) with atosiban (10 µg/mouse in 1µl, i.c.v.) on depressive-like behaviors inmalemice: FST (A), splash test (B), SPT
(C), and OFT (D and E). Values are showed as the mean ± S.E.M from 6 to 8 animals and were analyzed using one-way ANOVA followed by Tukey’s post hoc test. *P b 0.05, **P b 0.01 and
***P b 0.001 compared with the saline-treated control mice, #P b 0.05 and ##P b 0.01 compared with the saline-treated MS mice. OT: oxytocin and ATO: atosiban.
Table 3
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(P b 0.05 and P b 0.01, respectively).
3.5. Effects of MS and OT on nitrite levels in the hippocampus
Tukey's analysis determined that the nitrite level in the hippocam-
pus of MS mice is greater than controls (P b 0.001, Table 2). In compar-
ison with saline-treated MS mice, treatment with OT (1 μg/mouse in
1 μl) signiﬁcantly decreased hippocampal nitrite levels in MS animals
(P b 0.01).
3.6. Effects of MS and OT on ROS formation in the hippocampus
A signiﬁcant increase in hippocampal ROS formation was observed
in saline-treated MS mice at 3 time intervals when compared to
saline-treated controls (P b 0.001 for all, Table 3). OT (1 μg/mouse in
1 μl) signiﬁcantly decreased the elevated levels of ROS in the hippocam-
pus of MS mice when compared with saline-treated MS animals
(P b 0.001 for all). Furthermore, in comparison with saline-treatedTable 2
Effects of MS and oxytocin on GSH, ATP, and nitrite levels in the hippocampus. Values
expressed as mean ± S.E.M. (n = 3–6).
Groups
GSH (μg/mg
protein)
ATP
(nmol/mg
protein)
Nitrite
(nmol/mg
protein)
Control 11.3 ± 0.7 10.1 ± 0.1 74 ± 4
Maternal separation (MS) 6.2 ± 0.15** 5.5 ± 0.2** 122 ± 7***
Control + oxytocin (1 μg) 11.4 ± 0.6 10.6 ± 0.2 78 ± 6
MS + oxytocin (1 μg) 10.4
± 0.07##
9.9 ± 0.2## 97 ± 4##
Control + atosiban 7.2 ± 0.34** 8.1 ± 0.2* 70 ± 8
MS + atosiban 7.7 ± 0.7 5.5 ± 0.22 115 ± 6
Control + atosiban + oxytocin
(1 μg)
6.3 ± 0.11** 6.1 ± 0.18** 81 ± 7
MS + atosiban + oxytocin (1 μg) 7.1 ± 0.19 7.6 ± 0.3 123 ± 4
*P b 0.05, **P b 0.01 and ***P b 0.001 compared with control group and
##P b 0.01compared with MS group.controls, administration of atosiban and also co-administration of
atosiban with OT increased the hippocampal ROS levels (P b 0.001).
Moreover, atosiban signiﬁcantly enhanced ROS production in the hip-
pocampus of MS mice in compared to MS controls at 5 min
(P b 0.001) and 30 min (P b 0.001) intervals. Tukey's analysis showed
that at 5 min interval co-administration of atosiban with OT signiﬁcant-
ly increased the levels of ROS production in comparison with saline-
treated MS mice (P b 0.001).
3.7. Oxytocin decreased the expression of genes relevant to immune-
inﬂammatory responses in the hippocampus
Our results on the effects of OT treatment on the expression of genes
related to neuroinﬂammatory responses in the hippocampus are pre-
sented in Fig. 4. One-way ANOVA analysis showed that there are signif-
icant differences between experimental groups (F (39, 120) = 60.10,
P b 0.001, Fig. 4). Tukey's analysis demonstrated the overexpression ofEffects of MS as well as oxytocin on percent of ROS formation in the hippocampus. Data
represented as mean ± S.E.M. (n = 3–6).
Groups
DCF ﬂuorescence intensity (%)
5 min 30 min 60 min
Control + saline 0 2.1 ± 0.05 3.4 ± 0.1
MS + saline 30.1
± 0.8***
72.3 ± 2*** 122 ± 3.5***
Control + oxytocin (1 μg) 0 1.8 ± 0.03 4.2 ± 0.2
MS + oxytocin (1 μg) 0.2
± 0.01###
10.5
± 0.01###
11.9
± 0.5###
Control + atosiban 34.3
± 1.7***
65.1 ± 1.3*** 106.4
± 7.4***
MS + atosiban 97.4
± 3.6###
133.5
± 4.8###
144.3 ± 5.5
Control + atosiban + oxytocin
(1 μg)
54.3
± 1.5***
60.3 ± 2.1*** 124.5 ± 3***
MS + atosiban + oxytocin (1 μg) 52.3
± 2.4##
63.4 ± 2.2 142.5 ± 3.7
***P b 0.001 compared with control group and ##P b 0.01 and ###P b 0.001 compared
with MS+ saline group at the same time interval.
Fig. 4. Effect of oxytocin on hippocampal immune-inﬂammatory markers: Effect of intracerebroventricular saline and OT injections on Tnf-α, Il-1β, Nlrp-3, Tlr4, and Myd88 gene
expressions in the hippocampus of the animals, Data are expressed as the mean ± S.E.M and were analyzed by one-way ANOVA. ***P b 0.001 compared with the control group and
###P b 0.001 compared with MS group in each counterpart. OT:oxytocin, ATO: atosiban.
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and Nlrp-3 (P b 0.001) in the hippocampus of MS mice in comparison
with control animals. Our ﬁndings showed that following treatment
with OT (1 μg/mouse in 1 μl), the expression of Tnf-α, Il-1ß, Myd88,
Tlr4 and Nlrp-3 were signiﬁcantly reduced in the hippocampus of MS
micewhen compared to saline-treatedMSmice (Pb 0.001 for all). How-
ever, OT failed to made signiﬁcant differences in control mice when
compared to saline-treated controls. In addition, administration of
atosiban as well as co-administration of atosiban with OT did not
exert signiﬁcant changes in the expression of genes related to neuroin-
ﬂammation when compared to their control counterparts.
4. Discussion
In the current study, we demonestrated that experiencing MS is ca-
pable of provoking depressive-like behaviors in adult male mice. These
observed behavioral effects were associated with abnormal mitochon-
drial function and the increased expression of genes relevant to
immune-inﬂammatory responses in the hippocampus. Further, we
found that treating MS mice with OT signiﬁcantly mitigated the nega-
tive effects of MS on hippocampus and behavior. Our results showed
that OT has antidepressant properties against the effects of early lifestress through improvingmitochondrial function and reducing the neu-
roinﬂammation in the hipocampus.
Previous clinical and preclinical studies indicate that early life adver-
sities have long-lasting endocrinological, behavioral and neurochemical
effects on subjects. Since early relationship between infant and mother
plays a critical role in shaping the offspring neurochemical system, MS
as a stressful/traumatic event signiﬁcantly increases the risk of mental
disorders such as depression in adulthood (Kuhn and Schanberg,
1978; Kuhn et al., 1990; Matthews et al., 1996; Matthews and
Robbins, 2003; Nemeroff and Vale, 2005). Previously reported results
by our group have also shown that MS has negative effects on brain
and behavior of animals by altering the seizure threshold, pain re-
sponses, depressive-like behaviors and neurotransmission such as do-
paminergic system, opioid and OTergic systems (Amini-Khoei et al.,
2015, 2016; Amiri et al., 2016a).
Previous studies have demonestrated that there are deﬁcits in the
open ﬁeld activity of the animals which were chronically subjected to
several stressors (Katz et al., 1981; Willner et al., 1987). It is important
to note that there is an discrepancy between the results of different
studies about OFT following MS paradigm (Shalev and Kafkaﬁ, 2002;
Cannizzaro et al., 2006; Millstein and Holmes, 2007). Our results
showed that MS mice had increased vertical and horizontal activity in
176 H. Amini-Khoei et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 76 (2017) 169–178the OFT. In this study, we conducted the OFT to ensure that locomotor
activity of animals following MS or treatments does not affect the FST
results, and the immobility of animals in the FST is not associated with
their hypolocomotion. to (Amiri et al., 2016a). Also, our results showed
that MS can provoke depressive-like behaviors in FST, SPT and splash
test. FST is considered as a valid screening test for the evaluation of
novel antidepressants. In this test, immobility time of rodents following
experiencing the FST resemble to those passive behaviors of depressed
patients following exposure to unpredictable and unscapable stressful
conditions (Cryan and Holmes, 2005). In line with previous studies,
our results showed that MS mice had higher immobility time in FST in-
dicating the depressanteffect of MS on animals.
In addition to behavioral despair that we observed in FST results, an-
hedonia is another core symptom of depression that can be assessed by
applying SPT to rodents (Katz and Sibel, 1982; Willner, 1985; Wallace
et al., 2009). Our results showed a signiﬁcant decrease in the
cunsumption of sucrose indicating that MS is able to induce anhedonia
in animals. Additionally, splash test is known to assess the self-care
and motivational difﬁculties in rodents (Marrocco et al., 2014; Amiri
et al., 2015b). We observed that MS mice exhibited low response to
sucrose 10% (reduction in the grooming activity time) in the splash
test suggesting the negative effects of MS on self-care and motivation
behaviors.
Beyond serotonin hypothesis; role of inﬂammation, mitochondrial
dysfunction and social factors have been considered as new theories
for the pathogenesis od depression (Gardner and Boles, 2011; Maes,
2011; Slavich and Irwin, 2014). The elevated levels of pro-
inﬂammatory cytokines has been reported in depressed patients
(Maes et al., 1990, 2009; Blume et al., 2011). A study by Shelton and col-
leagues (Shelton et al., 2011) revealed an increase in the inﬂammatory
cytokines in the frontal cortex of the brain of depressed patients
which is involved in reward-related behavior.
Beyond the serotonin hypothesis, mitochondrial dysfunction and
oxidative stress has been shown to be involved in the pathophysiology
of depression (Tobe, 2013). In this regard, some studies have shown the
involvement of mitochondrial genes (mtDNA and nDNA), respiratory
chain enzyme ratios, and the rate of ATP production in the brain of de-
pressed subjects (Gardner et al., 2003; Shao et al., 2008; Gardner and
Boles, 2011). Chronic stress adversely affects the cellular energymetab-
olism throughmitochondrial dysfunction (Picard et al., 2014). Brain is a
highly active organ and mitochondria produce the ATP, which is neces-
sary for cell survival and function. Increasing lines of research suggest
that brain mitochondria not only are the ﬁrst targets of stress, but also
potently implicated in the pathophysiology of depression (Gardner
and Boles, 2011; Morava and Kozicz, 2013). Recent evidence suggests
the role of mitochondria in the production of damaged associated mo-
lecular patterns (DAMPs), which are released by the variety of cells
(such as neurons, glial and immune cells) under stressful conditions
(Krysko et al., 2011). Our results showed that abnormal mitochondrial
function was associated with high level of oxidative and nitrosative
stress (overproduction of ROS and NO), antioxidant impairment (de-
creased level of GSH) and impaired energy metabolism (decreased
ATP production). These alterations inmitochondrial function are associ-
ated with the production of DAMPs under stressful conditions (Krysko
et al., 2011). Since DAMPs are considered as endogenous ligands for
the stimulation of TLR4, overexpression of these receptors along with
main regulator of their signaling (MyD88 and TNF-α) suggests the in-
volvement of TLR4 in the pathophysiology of depression (Hänsel et al.,
2010; Liu et al., 2014). Considering the role of sterile inﬂammation in
the pathophysiology of affective disorders, increasing lines of research
have shown that mitochondrial dysfunction is associated with the acti-
vation of theNLRP3 that consequently instigates the expression of IL-1β
(Anisman, 2009; Gurung et al., 2015). In agreement with above men-
tioned studies, we showed that applying MS paradigm signiﬁcantly in-
creased the expression of genes relevant to neuro-inﬂammatory
response (Il-1β,Myd88, Tnf-α, Tlr4 and Nlrp3).The nine-amino-acid hypothalamic neuropeptide, OT, has a key role
in the regulation of neurotransmission, psychogenic stress, anxiety, de-
pression, social interaction, afﬁliative behaviors and emotion regulation
(Heinrichs et al., 2003; Lim and Young, 2006; Hoge et al., 2008; Schulze
et al., 2011). Focusing on the effects of OT on depression, Scantamburlo
and colleagues (Scantamburlo et al., 2011) investigated the effects of in-
tranasal OT as an adjunct to the antidepressant escitalopram in major
depression, and showed a signiﬁcant improvement in patients. Our re-
sult showed that administration of OT (i.c.v.) reveresed the effects of
MS on behaviors related to depression. In this regard, OT treatment de-
ceased the immobility time in the FST, Increased grooming activity time
in the splash test, and also increased the sucrose consumption in the
SPT. Our OFT results showed that OT decreased horizontal activity of
MS mice. These results showed that acute administration of OT is capa-
ble of producing antidepressant-like effects in mice subjected to early
life stress. These acute effects of OT suggest that early life stress is asso-
ciated with an abnormal signaling of OTergic system. It has been shown
that negative effects of MS are associated with epigenetic programming
of stress on expression of some genes (e.g. oxytocin (Oxt), Oxytocin re-
ceptor (Oxtr), and brain-derived neurotroﬁc factor or Bdnf). Thus, ab-
normal activity of OTergic system in MS mice maybe associated with
the silencing of mentioned genes that administration of OT could acute-
ly produce antidepressant effects (Roth et al., 2009; Kumsta et al., 2015).
Oxytocin regulates immune-inﬂammatory responses and has been
shown to have antioxidant and anti-inﬂammatory activities. In this re-
gard, inhibition of pro-inﬂammatory mediators such as TNF-α, IL-1β,
and inducible nitric oxide synthase have been reported for OT
(Düşünceli et al., 2008; Karelina et al., 2011; Akman et al., 2015; Yuan
et al., 2016). A research by Yuan et al. (Yuan et al., 2016) demonstrated
that OT has anti-neuroinﬂammatory effects and suggested that OT can
be used as potential therapeutic agent for the alleviation of
neuroinﬂammatory diseases associated with microglia activation. Fur-
ther, another study showed that OT is able to improve antioxidant
state and ameliorates oxidative injury (İşeri et al., 2005). In addition, an-
other study demonstrated that OT can decrease the progression of ath-
erosclerosis by decreasing NADPH-dependent superoxide activity and
IL-6 release (Szeto et al., 2008). Also, protective effects of OT against
free oxygen radicals, lipid peroxidation and also mitochondrial damage
in the brain have been reported (Moosmann and Behl, 2002; Erbaş et al.,
2012; Akman et al., 2015). In current study, we demonestrated that i.c.v.
administration of OT attenuated the negative effects of MS on mito-
chondrial function and neuroinﬂammatory state in the hipocampus.
Our ﬁndings showed that the expresion of genes related to neuroin-
ﬂammation (Il-1β,Myd88, Tnf-α, Tlr4 andNlrp3) signiﬁcantly decreased
in OT-treated MS mice when compared to controls. Moreover, OT suc-
cessfully improved mitochondrial function in MS mice by decreasing
the ROS formation, increasing ATP levels and GSH levels. We also
showed that OT decreased the NO levels in the hipocampus of MS ani-
mals. These results showed that OT has acute antidepressant-like effects
in adult male mice exposed to early life stress, and its effects are partly
associatedwith improvement of mitochondrial function and decreasing
the inﬂammatory factors in the hippocampus. Considering the safety
and rapid action of OT, further research is needed to clarify the potential
application of OT could as a clinical antidepressant in humans or atleast
as an adjuvant therapy to antidepressant for the treatment of
depression.
5. Conclusions
In conclusion, results of this study showed that: 1) Maternal separa-
tion, as an early life challenge, provoked depresive-like behaviors in
adult male mice, 2) adverse effects of MS were associated with abnor-
mal mitochondrial function and immune-inﬂammatory responses in
the hipocampus, 3) OT acutely mitigated the effects of MS on
depressive-like behaviors in male mice, 4) Beneﬁcial effects of OT
against the adverse effects of MS are partly associated with the
177H. Amini-Khoei et al. / Progress in Neuro-Psychopharmacology & Biological Psychiatry 76 (2017) 169–178improvement of mitochondrial function and attenuation of neuro-
inﬂammatory responses in the hipocampus.
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